Taro Sees ElixSure Licensing As Means To Building Consumer Awareness
This article was originally published in The Tan Sheet
Executive Summary
Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly
You may also be interested in...
Taro To Expand ElixSure Line, Posts 49% Sales Gain In 2003
Taro Pharmaceutical Industries will expand its ElixSure product line late in the second quarter with Children's ElixSure IB (ibuprofen) Oral Suspension
Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System
Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers
Taro ElixSure “Spill-Resistant” Cough/Cold Medicines For Children Debut
Taro Consumer Healthcare Products will back its new ElixSure line of cough/cold medicines for children with $22 mil. in promotional spending through 2004